Moderna Starts Human Trials For Its Revolutionary HIV Vaccine This Week
This week, the biotech company Moderna will start human trials for its HIV vaccine. The vaccine will be the first of its kind to use messenger RNA (mRNA), an approach that Moderna used in its effective COVID-19 vaccine.
The clinical trials will start on August 19 and end sometime around spring 2023, according to the National Institutes of Health’s trial registry. They will involve 56 HIV-negative participants aged 18 to 56. The participants will be given one or two forms of mRNA that cause the body to form defenses against an HIV infection.
As LGBTQ Nation reports, in the past, HIV vaccines used inactivated forms of the virus. However, previous trials showed that these forms didn’t produce any immune responses. In fact, researchers canceled one trial in Thailand during the 2000s after inactivated forms of the virus were found to actually increase people’s risk of catching HIV rather than preventing infections.
Instead, the Moderna trials will contain one of two different types of mRNA: mRNA-1644 and mRNA-1644v2. These get the body’s cells to develop a “protein spike” on their surfaces. These spikes are similar to those embedded by HIV on a cell’s surface when it begins to infect cells to reproduce. When the body recognizes the presence of the mRNA spike, it begins producing antibodies to protect against infection.
The mRNA may also allow scientists to make tweaks to the vaccine more easily.
“The mRNA platform makes it easy to develop vaccines against variants because it just requires an update to the coding sequences in the mRNA that code for the variant,” Rajesh Gandhi, MD, an infectious diseases physician at Massachusetts General Hospital and chair of the HIV Medicine Association, told the medical site Verywell.
This is especially helpful since HIV has been known to have mutated into at least 16 variants.
Moderna’s mRNA vaccines passed phase 1 testing earlier this year. Phase 1 trials test safety by administering different dose strengths and observing how the body and drug interact. Phase 2 trials test the vaccine’s overall effectiveness, and phase 3 trials will compare the safety and effectiveness of the new vaccine against the current HIV prevention medications.
If the vaccine successfully completes phase 3 testing, then Moderna can submit its studies for approval by the US Food and Drug Administration (FDA). Then, the FDA will conduct phase 4 trials for widespread testing and cost analysis.
If successful, the vaccine could then become widely available, helping end an epidemic that has ravaged the globe for over 40 years.
Read related myGwork articles here:
The Role of Cities in the HIV Prevention Strategy
New HIV Vaccine “Based On Moderna’s COVID Jab” Shows Huge Promise After First Human Trials
People Living With HIV Can Now Access COVID Vaccine Without Notifying GP
Breakthrough Trial For HIV Cure Sees First Case In Remission
Breakthrough Discovery In HIV Research Opens Path To Better Therapies
